NCT06096038View on ClinicalTrials.gov

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2028

Conditions
Head and Neck CancerRelapseRecurrentRefractory Cancer
Interventions
DRUG

Cyclophosphamide

cyclophosphamide 300 mg/meter square IV

DRUG

Fludarabine

fludarabine 30 mg/meter square IV × 3 days

BIOLOGICAL

Cell Therapy

the autologous T lymphocyte chimeric antigen receptor cells against the CSPG4 antigen iC9-CAR.CSPG4 T cell infusion iC9-CAR.CSPG4 T cell infusion

Trial Locations (1)

27599

RECRUITING

Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill

Sponsors

Collaborators (1)

Bellicum Pharmaceuticals
All Listed Sponsors
collaborator

Bellicum Pharmaceuticals

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

UNC Lineberger Comprehensive Cancer Center

OTHER